**RECEIVED**

NOV 06 2002

TECH CENTER 1600/2900

#6 1631

Atty. Dkt. No. SALK2150-1  
(088802-4902)**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Doucas et al.

Title: METHOD FOR THE IDENTIFICATION  
AND USE OF SUBSTANCES THAT  
MODULATE POD FUNCTION  
AND/OR STRUCTURE

Appl. No.: 09/990,255

Filing Date: 11/20/2001

Examiner: Unknown

Art Unit: 1631

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date below.

Stephen E. Reiter

(Printed Name)

Stephen E. Reiter

(Signature)

10/18/02

(Date of Deposit)

**RECEIVED**

OCT 25 2002

TECH CENTER 1600/2900

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**Commissioner for Patents  
Washington, D.C. 20231

Sir:

Applicants submit herewith copies of forms PTO-892 and PTO-1449 from the parent application, Serial No. 08/975,272, filed November 21, 1997. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**RECEIVED**

NOV 07 2002

OFFICE OF PETITIONS

**TIMING OF THE DISCLOSURE**

This Information Disclosure Statement is being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

**RELEVANCE OF EACH DOCUMENT**

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.


Respectfully submitted,

Date 10/18/02

FOLEY & LARDNER  
P.O. Box 80278  
San Diego, California 92138-0278  
Telephone: (858) 847-6711  
Facsimile: (858) 792-6773

By Stephen E. Reiter

Stephen E. Reiter  
Attorney for Applicant  
Registration No. 31,192

FORM PTO 1449 US Department of Commerce Patent and Trademark Office 	ATTY DOCKET NO.: SALK 2150	SERIAL NO.: 08/975,272
	APPLICANT(S): Doucas and Evans	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: Nov. 21, 1997	GROUP ART UNIT: 1313

**RECEIVED**

OCT 25 2002

**U.S. PATENT DOCUMENTS**

**TECH CENTER 1600/2900**

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
		NONE					

**FOREIGN PATENT DOCUMENTS**

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)
		NONE					

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)**

	Andre, et al., "The PML and PML/PAR $\alpha$ Domains: From Autoimmunity to Molecular Oncology and from Retinoic Acid to Arsenic <sup>1</sup> " <i>Experimental Cell Research</i> 229:253-260 (1996)
	Avantaggiati, et al., "Recruitment of p300/CBP in p53-Dependent Signal Pathways" <i>Cell</i> 89:1175-1184 (1997)
	Blondel, et al., "Efficient induction of focus formation in a subclone of NIH3T3 cells by <i>c-myc</i> and its inhibition by serum and by growth factors" <i>Oncogene</i> 5:857-865 (1990)
	Brazas and Ganem, "A Cellular Homolog of Hepatitis Delta Antigen: Implications for Viral Replication and Evolution" <i>Science</i> 274:90-94 (1996)
	Chiao, et al., "Autoregulation of I $\kappa$ B $\alpha$ activity" <i>Proc. Natl. Acad. Sci. USA</i> 91:28-32 (1994)
	Doucas and Evans, "The PML nuclear compartment and cancer" <i>Biochimica et Biophysica Acta</i> 1288:M25-M29 (1996)
	Doucas, et al., "Adenovirus replication is coupled with the dynamic properties of the PML nuclear structure" <i>Genes &amp; Development</i> 10:196-207 (1996)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**RECEIVED**


NOV 07 2002

**OFFICE OF PETITIONS**

**RECEIVED**

NOV 06 2002

**TECH CENTER 1600/2900**

FORM 1449 US Department of Commerce Patent and Trademark Office 	ATTY DOCKET NO.: SALK 2150	SERIAL NO.: 08/975,272
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT(S): Doucas and Evans	
	FILING DATE: Nov. 21, 1997	GROUP ART UNIT: 1313

	Doucas, et al., "The PML-retinoic acid receptor $\alpha$ translocation converts the receptor from an inhibitor to a retinoic acid-dependent activator of transcription factor AP-1" <i>Proc. Natl. Acad. Sci. USA</i> 90:9345-9349 (1993)
	Evans, "The Steroid and Thyroid Hormone Receptor Superfamily" <i>Science</i> 240:889-895 (1988)
	Gongora, et al., "Molecular Cloning of a New Interferon-induced PML Nuclear Body-associated Protein" <i>The Journal of Biological Chemistry</i> 272(31) 19457-19463 (1997)
	Hollengerg and Evans, "Multiple and Cooperative <i>Trans</i> -Activation Domains of the Human Glucocorticoid Receptor" <i>Cell</i> 55:899-906 (1988)
	Lowry, et al., "Protein Measurement with the Folin Phenol Reagent" <i>The Journal of Biological Chemistry</i> 193:265-274 (1951)
	Miller and Whelan, "Progress in Transcriptionally Targeted and Regulatable Vectors for Genetic Therapy" <i>Human Gene Therapy</i> 8:803-815 (1997)
	Naldini, et al., "In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector" <i>Science</i> 272:263-267 (1996)
	Ogryzko, et al., "The Transcriptional Coactivators p300 and CBP Are Histone Acetyltransferases" <i>Cell</i> 87:953-959 (1996)
	Rottman, et al., "A Retinoic Acid-Responsive Element in the Apolipoprotein AI Gene Distinguishes between Two Different Retinoic Acid Response Pathways" <i>Molecular and Cellular Biology</i> 11(7) 3814-3820 (1991)
	Tontonoz, et al., "Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor $\gamma$ and the retinoid X receptor" <i>Proc. Natl. Acad. Sci. USA</i> 94:237-241 (1997)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449  
 GT6077133.1  
 62574-992150

RECEIVED

NOV 07 2002

OFFICE OF PETITIONS

RECEIVED


NOV 06 2002

TECH CENTER 1600/2900

RECEIVED

OCT 25 2002

TECH CENTER 1600/2900

 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO.: SALK 2150	SERIAL NO.: 08/975,272
	APPLICANT(S): Doucas and Evans	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: Nov. 21, 1997	GROUP ART UNIT: 1313

		Tsai and O'Malley, "MOLECULAR MECHANISMS OF ACTION OF STEROID/THYROID RECEPTOR SUPERFAMILY MEMBERS". <i>Annu. Rev. Biochem.</i> 63:451-486 (1994)
		Wahli and Martinez, "Superfamily of steroid nuclear receptors: positive and negative regulators of gene expression" <i>The FASEB Journal</i> 5:2243-2249 (1991)
		Wet, et al, "Firefly Luciferase Gene: Structure and Expression in Mammalian Cells" <i>Molecular and Cellular Biology</i> 7(2) 725-737 (1987)
		Wilson, J. M., "Vectors - shuttle vehicles for gene therapy" <i>Clin Exp Immunol</i> 107 (Suppl. 1):31-32 (1997)

RECEIVED

NOV 06 2002

TECH CENTER 1600/2900

RECEIVED

OCT 25 2002

TECH CENTER 1600/2900


RECEIVED

NOV 07 2002

OFFICE OF PETITIONS

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<b>Notice of References Cited</b>	Application No. <b>08/975,272</b>	Applicant(s) <b>Doucas et al.</b>	
	Examiner <b>John S. Brusca</b>	Group Art Unit <b>1636</b>	Page 1 of 1

**U.S. PATENT DOCUMENTS**

	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS
A					
B					
C					
D					
E					
F					
G					
H					
I					
J					
K					
L					
M					

**RECEIVED**  
OCT 25 2002  
TECH CENTER 1600/2900  
**RECEIVED**  
NOV 06 2002  
TECH CENTER 1600/2900

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUBCLASS
N						
O						
P						
Q						
R						
S						
T						

**NON-PATENT DOCUMENTS**

	DOCUMENT (Including Author, Title, Source, and Pertinent Pages)	DATE
U	Stadler et al. Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element. Oncogene Vol. 11, pages 2565-2573	1995
V		
W		
X		

**RECEIVED**  
NOV 07 2002  
OFFICE OF PETITIONS